Hydrocortisone + Placebo
ApprovedTerminated 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Partial Corticotrope Insufficiency
Conditions
Partial Corticotrope Insufficiency
Trial Timeline
Feb 1, 2010 → Mar 1, 2015
NCT ID
NCT01089075About Hydrocortisone + Placebo
Hydrocortisone + Placebo is a approved stage product being developed by Novo Nordisk for Partial Corticotrope Insufficiency. The current trial status is terminated. This product is registered under clinical trial identifier NCT01089075. Target conditions include Partial Corticotrope Insufficiency.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01089075 | Approved | Terminated |
Competing Products
20 competing products in Partial Corticotrope Insufficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E2007 | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| perampanel + perampanel | Eisai | Phase 1 | 33 |
| perampanel + perampanel + perampanel + Placebo | Eisai | Phase 3 | 77 |
| Perampanel + Placebo | Eisai | Approved | 85 |
| Perampanel and Microgynon-30 + Perampanel and Microgynon-30 | Eisai | Phase 1 | 33 |
| perampanel | Eisai | Phase 2 | 52 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| zonisamide | Eisai | Pre-clinical | 23 |
| E2007 (perampanel) + E2007 (perampanel) + Placebo | Eisai | Phase 3 | 77 |
| Perampanel + Placebo | Eisai | Phase 3 | 77 |
| E2007 (perampanel) + E2007 (perampanel) + Placebo | Eisai | Phase 3 | 77 |
| Adjunctive Zonisamide + Replacement with Zonisamide | Eisai | Approved | 85 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Rufinamide | Eisai | Phase 3 | 77 |
| Zonisamide | Eisai | Phase 3 | 77 |
| Eslicarbazepine Acetate tablets | Eisai | Pre-clinical | 23 |